STRATEGIC ADVISORY COMMITTEE
Lluís Gómez, PhD
Scientific Director, Draconis Pharma
Dr. Gómez is currently Scientific Director at Draconis Pharma. He previously trained his expertise in drug development as project leader in J. Uriach & Cia. since year 1983 to 2000. During these years, he developed several preclinical projects related with different circulatory system responses. Later on, he was appointed as Head of Screening for the same company, being focused on the level of in vitro, in vivo and ADME/PK studies. In his current position in Draconis, he is still a scientific model in the field of in vitro, in vivo and ADMET screening.
Muddasar Farooq, PhD
CEO, Kirklees Biosciences
Dr. Farooq is already starting his own biotecnology commercial endeavour with Kirklees Biosciences. He has a long track recording of ADME and Cancer research experience. His expertise in drug discovery is a major asset for Kirklees, and was trained first in GlaxoSmithKline, Ferring Pharmaceuticals and finally in Cancer Research Technology for almost ten years. He exhibits a deep knowledge in the DMPK area, as well as in bioanalysis and method development.
Francesc Mitjans, PhD
CSO, Lykera Biomed
Dr. Mitjans is currently director of the Biomed Division of Leitat Technological Center (2008), where he steers the activities of the division. He is also Chief Scientific Officer at Lykera Biomed (2011), a biotech company dealing with innovative therapeutic and diagnostic oncology projects. He has over 15 years of experience in the pharmaceutical industry as Department Head at Merck-Serono, leading projects for preclinical and clinical development of new drugs and specially monoclonal antibodies in the area of tumor angiogenesis, tumor progression and metastasis.
Sandy is one of the co-founders of ADMEcell, a San Francisco based biotechnology company developing and marketing innovating Ready-to-Use Kits to assist and stream line drug development especially in the DMPK area. ADMEcell is Readycell’s exclusive partner in the United States. Sandy has over 25 years business and marketing experience in the in-vitro assay field between the diagnostic and drug development industries. Previously, Sandy was the founder of BiosPacific, an antibody manufacturer and supplier to the diagnostic industry. Biospacific pioneered antibodies to Troponin I for early detection of heart attacks. R & D Systems, a USA based company, acquired BiosPacific in 2005.
Josep Oriol Nicolas, PhD
CEO, Nostrum Biodiscovery
Dr. Nicolas is currently CEO of Nostrum Biodiscovery, a leading bioinformatic company focused in drug discovery. Oriol was previously involved as a Manager and CEO of ReadyCell several years. He started his career in Almirall, holds a PhD and MBA of Pharmaceutical industry. Also dedicated several years to international technology transfer management and technology brokerage in a strategic consultancy firm.
Jordi Gracia Sancho, PhD
Head, of the Liver Vascular Biology
Jordi is the Head of the Liver Vascular Biology Research Group at the IDIBAPS Biomedical Research Institute, in Barcelona. He obtained the PhD at the University of Barcelona Medical School, and received post-doctoral training at Harvard Medical School. In 2012 he obtained the “Ramón y Cajal” Spanish tenure-track position. Dr Gracia-Sancho is considered a KOL in liver disease pathophysiology, indeed he has (co-)authored more than 50 peer-reviewed original papers and reviews, and serves as consultant for some of the most relevant pharmaceutical companies developing drugs for liver disease. In 2016 he received the Young Investigator Award from European Association for the Study of the Liver (EASL).